Ecor1 Capital buys $18,405,720 stake in Dermira Inc (DERM)

Dermira Inc (DERM) : Ecor1 Capital scooped up 250,000 additional shares in Dermira Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 522,000 shares of Dermira Inc which is valued at $18,405,720.Dermira Inc makes up approximately 6.58% of Ecor1 Capital’s portfolio.

Other Hedge Funds, Including , Raymond James Associates boosted its stake in DERM in the latest quarter, The investment management firm added 5,171 additional shares and now holds a total of 59,856 shares of Dermira Inc which is valued at $2,110,523. Dermira Inc makes up approx 0.01% of Raymond James Associates’s portfolio. Granite Point Capital Management added DERM to its portfolio by purchasing 27,000 company shares during the most recent quarter which is valued at $913,950. Dermira Inc makes up approx 0.81% of Granite Point Capital Management’s portfolio.Diam Ltd. boosted its stake in DERM in the latest quarter, The investment management firm added 3,836 additional shares and now holds a total of 11,623 shares of Dermira Inc which is valued at $344,273. Dermira Inc makes up approx 0.01% of Diam Ltd.’s portfolio.Swiss National Bank boosted its stake in DERM in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 34,900 shares of Dermira Inc which is valued at $1,033,738. Ifp Advisors Inc added DERM to its portfolio by purchasing 11 company shares during the most recent quarter which is valued at $315.

Dermira Inc closed down -0.39 points or -1.15% at $33.6 with 1,00,020 shares getting traded on Monday. Post opening the session at $34.13, the shares hit an intraday low of $33.37 and an intraday high of $34.52 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.

Leave a Reply

Dermira Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dermira Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.